Literature DB >> 15185352

Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan.

Amy Pickard1, Chien-Jen Chen, Scott R Diehl, Mei-Ying Liu, Yu-Juen Cheng, Wan-Lun Hsu, Brenda Sun, Mow-Ming Hsu, I-How Chen, Jen-Yang Chen, Czau-Siung Yang, Beth L Mittl, Sheng-Ping Chou, Deborah D Ruggles, Alisa M Goldstein, Allan Hildesheim.   

Abstract

Most adults have been infected with EBV. Many studies have indicated that antibodies against specific EBV antigens, particularly IgA antibodies, can be predictive or prognostic of EBV-associated malignancies, such as NPC. We hypothesized that healthy individuals from families with a history of multiple members affected with NPC (who therefore might be genetically susceptible to NPC themselves) might have an EBV antibody profile that is distinct from that seen in healthy individuals from the community at large. To explore this possibility and examine determinants of anti-EBV antibody levels in healthy, high-risk individuals, we evaluated data from 2 parallel studies of NPC in Taiwan, which included 1,229 healthy members of families in which 2 or more individuals were affected with NPC and 320 controls from the community at large. Blood collected from participants was tested for IgA antibodies against EBV VCA and EBNA-1 and for neutralizing antibodies against EBV DNase using standard assays. We observed evidence of familial aggregation of EBV seroreactivity among individuals from high-risk, multiplex NPC families. Anti-VCA IgA and anti-EBNA-1 IgA antibody seroprevalence in unaffected family members of NPC cases was 5-6 times higher than in members of the community (p < 0.01). This elevated seroprevalence among unaffected individuals from high-risk families was observed regardless of the relationship of the unaffected individual to the closest affected relative (siblings, parents, children or spouses). No sociodemographic or environmental factors examined were found to strongly and consistently correlate with elevated seroprevalence, but patterns emerged of increasing seroprevalence among older individuals and among females. Unaffected individuals from high-risk NPC families have elevated anti-EBV IgA antibody titers. The etiologic and clinical implications of this finding remain to be established. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15185352     DOI: 10.1002/ijc.20222

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.

Authors:  Allan Hildesheim; Denise L Doolan; Anna E Coghill; Ruth M Pfeiffer; Carla Proietti; Wan-Lun Hsu; Yin-Chu Chien; Lea Lekieffre; Lutz Krause; Andy Teng; Jocelyn Pablo; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Zhiwei Liu; Chien-Jen Chen; Jaap Middeldorp; Jason Mulvenna; Jeff Bethony
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

2.  Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.

Authors:  Anna E Coghill; Wan-Lun Hsu; Ruth M Pfeiffer; Hedy Juwana; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Jen-Yang Chen; Chien-Jen Chen; Jaap M Middeldorp; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-27       Impact factor: 4.254

3.  Elevated antibodies against Epstein-Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants.

Authors:  Anna E Coghill; Wan-Lun Hsu; Qi Yang; Cheng-Ping Wang; Pei-Jen Lou; Kelly J Yu; Guoqin Yu; Scott R Diehl; Chien-Jen Chen; Alisa M Goldstein; Allan Hildesheim
Journal:  J Gen Virol       Date:  2018-07-05       Impact factor: 3.891

4.  High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.

Authors:  Anna E Coghill; Wei Bu; Hanh Nguyen; Wan-Lun Hsu; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Chien-Jen Chen; Allan Hildesheim; Jeffrey I Cohen
Journal:  Clin Cancer Res       Date:  2016-02-26       Impact factor: 12.531

5.  Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.

Authors:  Kelly J Yu; Wan-Lun Hsu; Ruth M Pfeiffer; Chun-Ju Chiang; Cheng-Ping Wang; Pei-Jen Lou; Yu-Juen Cheng; Patti Gravitt; Scott R Diehl; Alisa M Goldstein; Chien-Jen Chen; Allan Hildesheim
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

6.  EBV seroepidemiology in married and unmarried women and men in Iran.

Authors:  Morteza Pourahamad; Farhang Hooshmand; Sara Olyaee Nezhad; Abdolali Sepidkar
Journal:  Rep Biochem Mol Biol       Date:  2014-04

7.  Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.

Authors:  Nehla Mokni Baizig; Patrice Morand; Jean Marie Seigneurin; Hamouda Boussen; Asma Fourati; Said Gritli; Zeineb Oueslati; Slim Touati; Amor Gamoudi; Mansour Ben Abdallah; Michèle El May; Ahmed El May
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-30       Impact factor: 2.503

8.  Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.

Authors:  Cindy Chang; Jaap Middeldorp; Kelly J Yu; Hedy Juwana; Wan-Lun Hsu; Pei-Jen Lou; Cheng-Ping Wang; Jen-Yang Chen; Mei-Ying Liu; Ruth M Pfeiffer; Chien-Jen Chen; Allan Hildesheim
Journal:  J Med Virol       Date:  2012-12-21       Impact factor: 2.327

9.  Comparison of narrow-band imaging and conventional nasopharyngoscopy for the screening of unaffected members of families with nasopharyngeal carcinoma.

Authors:  Ching-Yin Ho; Kee-Tak Chan; Pen-Yuan Chu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-23       Impact factor: 2.503

10.  Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.

Authors:  Ai-Di Gu; Li-Xia Lu; Yan-Bo Xie; Li-Zhen Chen; Qi-Sheng Feng; Tiebang Kang; Wei-Hua Jia; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.